Molecular and genetic profile of head and neck squamous cell carcinoma

To determine the molecular pathways of head and neck squamous cell carcinoma (HNSCC) tumorogenesis there are held a great amount of investigations. New therapeutic models for HNSCC are discussed considering genetic and biochemical specifications and taking in account significant scientific strategies. Dividing HNSCC into 2 large groups in accordance to human papilloma virus (HPV) association with different survival rates is a great achievement of the last decades in carcinogenesis researching and treatment of HNSCC. It is well known that chemical carcinogens are the main cause of HPV-negative tumors development. HPV-positive HNSCC is associated with E6 and E7 HPV proteins. The results of whole exome sequencing of HNSCC are of the great interest. Molecular expression profile of Rb-E2F/p53 were diff erent in HPV-positive and HPV-negative tumors. The phosphorylated pRb and p16 proteins analysis showed low pRb and high p16 levels in HPV-positive tumors in contrast to HPV-negative samples due to the HPV E7 ability to degrade Rb. P16 expression was higher in HPV-positive tumors, so it is immunohystochemical marker of HPV-positive status. The p53 expression pattern is determined also to identify its mechanism of degradation in HPV-positive tumors. Due to carcinogenic HPV ability by inactivation of cell cycle regulators р53 and pRb with the help of E6 and E7 oncoproteins, mutations of TP 53 shouldn’t play leading role in HPV-induced tomorogenity. Nevertheless, there are controversial data concerning HPV-positive tumors that part of them gain p53-mutations at the same time having integrated HPV-genome. The p53 expression in HPV-positive samples was the same as if in the absence of HPV.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi: 0.3322/caac.21254

2. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62(1):10–29. doi: 10.3322/caac.20138

3. Ragin CC, Modugno F, Gollin SM. Th e epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007; 86:104-14. doi: 10.1177/154405910708600202

4. Brockstein BE, Vokes EE. Head and neck cancer in 2010: Maximizing survival and minimizing toxicity. Nat Rev Clin Oncol. 2011;8(2):72–74. doi: 10.1038/nrclinonc.2010.226

5. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck cancer. Nature. 2015;517:576–582. doi: 10.1038/nature14129.

6. Galloway DA, Laimins LA. Human papillomaviruses: shared and distinct pathways for pathogenesis. Curr Opin Virol 2015;14:87–92. doi: 10.1016/j.coviro.2015.09.001.

7. ohnson ME, Cantalupo PG, Pipas JM. Identification of head and neck cancer subtypes based on human papillomavirus presence and E2F-regulated gene expression. mSphere. 2018;3(1):pii: e00580-17. doi: 10.1128/ mSphere.00580-17.

8. Rothenberg SM, Ellisen LW. Th e molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012;122(6):1951. doi: 10.1172/JCI59889

9. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, et al. Mutational landscape and significance across 12 major cancer types. Nature.2013;502:333–339. doi: 10.1038/nature12634

10. Leroy B, Fournier J.L, Ishioka C, Monti P, Inga A, et al. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. Nucleic Acids Res. 2013;41(Database issue):D962-9. doi: 10.1093/nar/gks1033

11. Wang Y, Suh YA, Fuller MY, Jackson J.G, Xiong S, et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J. Clin. Invest. 2011;121,893–904. doi: 10.1172/jci44504

12. Stricker TP, Neoplasia KV. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease.8th ed.Philadelphia, PA: Elsevier; 2010.

13. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell. 1992;70:523-526. doi: 10.1016/0092-8674(92)90421-8

14. Bougeard G, Sesboue R, Baert-Desurmont S, Vasseur S, Martin C, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J. Med. Genet. 2008;45:535–538. doi: 10.1136/jmg.2008.057570

15. Zerdoumi Y, Aury-Landas J, Bonaı¨ti-Pellie C, Derambure C, Sesboue´ R, et al. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. Hum. Mutat. 2013;34:453–461. doi: 10.1002/humu.22254

16. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigen- esis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 2010;222:129–137. doi: 10.1002/path.2748

17. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010;107:246–251. doi: 10.1073/pnas.0908428107

18. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. Mutant p53 gain of function in two mouse models of LiFraumeni syndrome. Cell. 2004;119:847–860. doi: 10.1016/j.cell.2004.11.004

19. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, et al. A Mutant- p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell. 2009;137:87–98. doi: 10.1016/j.cell.2009.01.039

20. Grugan KD, Vega ME, Wong GS, Diehl JA, Bass AJ, et al. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol. Ther. 2013;14(9):853-859. doi: 10.4161/cbt.25406

21. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009;139:1327–1341. doi: 10.1016/j.cell.2009.11.026

22. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, et al. Mutant p53 enhances MET traffi cking and signalling to drive cell scattering and invasion. Oncogene.2012;32:1252–1265. doi: 10.1038/onc.2012.148

23. Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29:2628–2637. doi: 10.1038/onc.2010.24

24. Wang W, Cheng B, Miao L, Mei Y, Wu M. Mutant p53-R273H gains new function in sustained activation of EGFR signaling via sup- pressing miR-27a expression. Cell Death Dis. 2013;4:e574. doi: 10.1038/cddis.2013.97

25. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene. 2007;26:2202-2211. doi: 10.1038/sj.onc.1210294

26. Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, et al. Wildtype and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle. 2013;12:278–288. doi: 10.4161/cc.23054

27. Frank AK, Pietsch EC, Dumont P, Tao J, Murphy ME. Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol. Ther. 2011;11:740–745. doi: 10.4161/cbt.11.8.14906

28. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, et al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle.2008;7:3056–3061. doi: 10.4161/cc.7.19.6751

29. Brazdova M, Navratilova L, Tichy V, Nĕmcova K, Lexa M, et al. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PLoS ONE. 2013;8:e59567. doi: 10.1371/journal.pone.0059567

30. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 2001;21:1874–1887. doi: 10.1128/mcb.21.5.1874-1887.2001

31. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem.2002;277:18817–18826. doi: 10.1074/jbc.m201405200

32. McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA. 2011;108:2130 – 2135. doi: 10.1073/pnas.1009933108.

33. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res.1996;56:3630 –3633. doi: 10.1016/s0194-5998(97)80093-9

34. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical as- sociations and future developments. Cell Cycle.2011;10:2497–2503. doi: 10.4161/cc.10.15.16776.

35. Saad HM, Al-Hijazi AY, Khashman BM. P53-tumor suppressor gene overexpression in human papilloma virus-infected patients with oral squamous cell carcinoma. J Bagh College Dentistry. 2011;23:70-76.

36. Badulescu F, Badulescu A, Crisan A, Popescu FC. Study of the diagnosis and treatment of cancer located in the head and neck and correlation with expression of prognostic markers. Rom J Morphol Embryol. 2013;54(3):487–497.

37. Wang Z, Xia R-H, Ye D-X, Li J. Human Papillomavirus 16 Infection and TP53 Mutation: Two Distinct Pathogeneses for Oropharyngeal Squamous Cell Carcinoma in an Eastern Chinese Population. PLoS ONE. 2016;11(10):e0164491. doi: 10.1371/journal.pone.0164491